Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comprehensive Treatment of Early Course Schizophrenia
NCT05662306Phase 4Terminated
- Sponsor
- University of Miami
- Start
- Jan 2024
- Primary completion
- Mar 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aripiprazole lauroxil in schizophrenia, sponsored by University of Miami. Primary endpoint: Percentage of Participants Who Develop Sustained Remission of Symptoms of Schizophrenia at 6 months. Started Jan 2024; status: terminated.
02
Drugs
aripiprazole lauroxil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05662306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662306.